JP2023534793A5 - - Google Patents

Info

Publication number
JP2023534793A5
JP2023534793A5 JP2023501378A JP2023501378A JP2023534793A5 JP 2023534793 A5 JP2023534793 A5 JP 2023534793A5 JP 2023501378 A JP2023501378 A JP 2023501378A JP 2023501378 A JP2023501378 A JP 2023501378A JP 2023534793 A5 JP2023534793 A5 JP 2023534793A5
Authority
JP
Japan
Prior art keywords
seq
cancer
protein
sequence
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023501378A
Other languages
English (en)
Japanese (ja)
Other versions
JP7819944B2 (ja
JP2023534793A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/056106 external-priority patent/WO2022009123A1/en
Publication of JP2023534793A publication Critical patent/JP2023534793A/ja
Publication of JP2023534793A5 publication Critical patent/JP2023534793A5/ja
Application granted granted Critical
Publication of JP7819944B2 publication Critical patent/JP7819944B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023501378A 2020-07-09 2021-07-07 Il-2バリアント Active JP7819944B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063050068P 2020-07-09 2020-07-09
US63/050,068 2020-07-09
PCT/IB2021/056106 WO2022009123A1 (en) 2020-07-09 2021-07-07 Il-2 variants

Publications (3)

Publication Number Publication Date
JP2023534793A JP2023534793A (ja) 2023-08-14
JP2023534793A5 true JP2023534793A5 (cg-RX-API-DMAC7.html) 2024-07-16
JP7819944B2 JP7819944B2 (ja) 2026-02-25

Family

ID=79552299

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023501378A Active JP7819944B2 (ja) 2020-07-09 2021-07-07 Il-2バリアント

Country Status (6)

Country Link
US (1) US20230242607A1 (cg-RX-API-DMAC7.html)
EP (1) EP4185605A4 (cg-RX-API-DMAC7.html)
JP (1) JP7819944B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230037612A (cg-RX-API-DMAC7.html)
CN (1) CN115768788A (cg-RX-API-DMAC7.html)
WO (1) WO2022009123A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022053864A1 (en) * 2020-09-08 2022-03-17 Kwon Byoung S Pd-1 polypeptide variants
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN114853909A (zh) * 2022-05-13 2022-08-05 南京吉盛澳玛生物医药有限公司 新型IL-2与INFα和Fc融合蛋白的设计、制备及用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088446A1 (en) * 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CN105440123B (zh) * 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
JP6640834B2 (ja) * 2014-08-11 2020-02-05 デリニア, インコーポレイテッド 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体
WO2016100375A2 (en) * 2014-12-15 2016-06-23 Washington University Compositions and methods for targeted cytokine delivery
AU2018287317B2 (en) * 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
JP7765181B2 (ja) * 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたil-2 fc融合タンパク質
CU24554B1 (es) * 2018-05-07 2021-11-04 Ct Inmunologia Molecular Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
US12522640B2 (en) * 2018-07-24 2026-01-13 BioNTech SE IL2 agonists
CA3098930A1 (en) * 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
CN113286812B (zh) * 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
CA3117853A1 (en) * 2018-10-29 2020-05-07 1Globe Biomedical Co., Ltd. Novel rationally designed protein compositions
AU2020285636A1 (en) * 2019-05-24 2021-11-04 Proviva Therapeutics (Hong Kong) Limited IL-2 compositions and methods of use thereof
EP4172216A4 (en) * 2020-06-24 2024-12-04 Medicenna Therapeutics, Inc. BIFUNCTIONAL SUPERKINE AND USES THEREOF
IL304365B2 (en) * 2021-03-31 2025-04-01 Hanmi Pharmaceutical Co Ltd A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof

Similar Documents

Publication Publication Date Title
Shi et al. Combining oncolytic viruses with cancer immunotherapy: establishing a new generation of cancer treatment
CN110872577B (zh) 修饰的免疫细胞及其应用
Edeline et al. CAR-T cells and BiTEs in solid tumors: challenges and perspectives
US9611325B2 (en) Construction and application of bispecific antibody HER2xCD3
EP3589308A1 (en) Therapeutic rna
WO2020037206A4 (en) Recombinant myxoma viruses and uses thereof
JP2022533957A5 (cg-RX-API-DMAC7.html)
WO2023151346A1 (zh) 一种新型双特异性嵌合抗原受体的构建及其应用
CN110437340B (zh) 双靶点识别可调控工程化免疫细胞的制备方法
Ma et al. Harnessing natural killer cells for lung cancer therapy
Li et al. Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments
Qian et al. Recent advances in adoptive cell therapy for cancer immunotherapy
CN110564767A (zh) 一种减毒病毒载体系统及其在制备抗恶性肿瘤的药物中的应用及药物使用方法
CN104558192A (zh) 一种双特异性抗体her2xcd3的构建及应用
CN115925940B (zh) 特异性结合cd47的抗体、其重组溶瘤病毒及其用途
CN115232217B (zh) 一种SynNotch结构及其应用
Yang et al. Advancing liver cancer treatment with dual-targeting CAR-T therapy
WO2022009123A4 (en) Il-2 variants
Zhu et al. Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors
Dash et al. Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review
EP4458862A1 (en) Bispecific t-cell engager, recombinant oncolytic virus thereof, and use thereof
CN106117367A (zh) 一种her‑3特异性嵌合抗原受体及其应用
CN117003897B (zh) 靶向Claudin18.2的CAR-T细胞及其用途
CN111732665B (zh) 一种靶向表达癌胚抗原的细胞的嵌合抗原受体
CN117126290A (zh) 双特异性抗体与nk细胞联合在治疗疾病中的应用